Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423103 | 0.85 | DGAT1 (0.37) | DGAT1BRD4CREBBP | |
| SCHEMBL17675396 | 0.81 | DGAT1 (0.39) | DGAT1BRD4CREBBPKLKB1 | |
| SCHEMBL31631873 | 0.79 | DGAT1 (0.36) | DGAT1BRD4CREBBP | |
| SCHEMBL15694427 | 0.78 | DGAT1 (0.38) | DGAT1BRD4CREBBPKLKB1 | |
| SCHEMBL31631794 | 0.78 | DGAT1 (0.38) | DGAT1BRD4CREBBPKLKB1 | |
| SCHEMBL26693951 | 0.78 | DGAT1 (0.35) | DGAT1BRD4CREBBPKLKB1 | |
| SCHEMBL12118691 | 0.74 | DGAT1 (0.44) | DGAT1BRD4CREBBP | |
| SCHEMBL31631753 | 0.74 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL23246344 | 0.74 | DGAT1 (0.33) | DGAT1BRD4CREBBPKLKB1 | |
| SCHEMBL22144010 | 0.74 | DGAT1 (0.40) | DGAT1BRD4CREBBPKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025125665-A1 | FURTHER SUBSTITUTED IMIDAZOLES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2025-06-19 | — | — | WO | disclosed |
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | REDX PHARMA PLC (GB) | 2025-01-21 | — | — | US | disclosed |
| US-20230365549-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2023-11-16 | — | — | US | disclosed |
| US-11643408-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | REDX PHARMA PLC (GB) | 2023-05-09 | — | — | US | disclosed |
| EP-3368036-B1 | MACROCYCLIC PYRIDINE-N-OXIDE DERIVATIVES AS FACTOR XIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-3204378-B3 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2022-05-25 | — | — | EP | disclosed |
| US-20210046076-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2021-02-18 | — | — | US | disclosed |
| US-10793560-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | REDX PHARMA PLC (GB) | 2020-10-06 | — | — | US | disclosed |
| EP-3204378-B1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2019-07-10 | — | — | EP | disclosed |
| US-20180339977-A1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-11-29 | — | — | US | disclosed |
| US-20180319788-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2018-11-08 | — | — | US | disclosed |
| US-20170275276-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2017-09-28 | — | — | US | disclosed |
| EP-3204378-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | Redx Pharma PLC (GB) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055786-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | WNT1, WNT3, CTNNB1 | DGAT1 3114/4885BRD4 572/4885CREBBP 359/4885 |
| US-10793560-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | WNT1, WNT3, CTNNB1 | DGAT1 3053/4885BRD4 847/4885CREBBP 213/4885 |
| US-20230365549-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | DGAT1 3114/4885BRD4 572/4885CREBBP 359/4885 |
| US-20180319788-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | DGAT1 3053/4885BRD4 847/4885CREBBP 213/4885 |
| US-20170275276-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | DGAT1 3053/4885BRD4 847/4885CREBBP 213/4885 |
| US-20210046076-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | DGAT1 3114/4885BRD4 572/4885CREBBP 359/4885 |
| US-20180339977-A1 | FACTOR XIA INHIBITORS | F11, SERPINC1, TFPI | DGAT1 2294/4885BRD4 2500/4885CREBBP 3145/4885 |
| US-11643408-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | WNT1, WNT3, CTNNB1 | DGAT1 3114/4885BRD4 572/4885CREBBP 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.